脉血康胶囊联合丹参川芎嗪注射液治疗短暂性脑缺血发作的临床研究

目的观察脉血康胶囊联合丹参川芎嗪注射液治疗短暂性脑缺血发作的临床疗效。方法选取2015年1月—2015年12月陕西省丹凤县医院收治的短暂性脑缺血发作患者106例,随机分为对照组和治疗组,每组各53例。对照组在常规治疗基础上静脉滴注丹参川芎嗪注射液,10 m L加入250 m L生理盐水,1次/d;治疗组在对照组的基础上口服脉血康胶囊,4粒/次,1次/d。两组患者均连续治疗4周。观察两组临床疗效,比较两组治疗前后凝血酶原时间(PT)、活化部分凝血活酶时间(APTT)、凝血酶时间(TT)、纤维蛋白原(FIB)、超敏C反应蛋白(hs-CRP)和D-二聚体指标水平。观察两组患者的不良反应和6个月内的复发情况。结果治疗后,对照组和治疗组的总有效率分别为69.81%、88.68%,两组比较差异具有统计学意义(P0.05)。治疗后,两组PT、APTT、TT水平均显著升高,FIB、hs-CRP、D-二聚体水平显著降低,同组治疗前后差异具有统计学意义(P0.05);且治疗组这些观察指标的改善程度优于对照组,两组比较差异有统计学意义(P0.05)。治疗组6个月复发率明显低于对照组,两组比较差异有统计学意义(P0.05)。结论脉血康胶囊联合丹参川芎嗪注射液治疗短暂性脑缺血发作临床疗效确切,不良反应少,具有一定的临床推广应用价值。

Clinical study on Maixuekang Capsules combined with Salviae Miltiorrhizae and Ligustrazine Hydrochloride Injection in treatment of transient ischemic attack

Objective To observe the clinical effect of Maixuekang Capsules combined with Salviae Miltiorrhizae and Ligustrazine Hydrochloride Injection in treatment of transient ischemic attack. Methods Patients (106 cases) with transient ischemic attack in Danfeng County Hospital in Shaanxi Province from January 2015 to December 2015 were randomly divided into control and treatment groups, each group had 53 cases. The patients in the control group were iv administered with Salviae Miltiorrhizae and Ligustrazine Hydrochloride Injection, 10 mL added into normal saline 250 mL, once daily. The patients in the treatment group were po administered with Maixuekang Capsules on the basis of the control group, 4 grains/time, once daily. The patients in two groups were treated for 4 weeks. After treatment, the efficacy was evaluated, and the levels of PT, APTT, TT, FIB, hs-CRP, and D-dimer in two groups before and after treatment were compared. The adverse reactions and recurrence within 6 months in two groups were observed. Results After treatment, the efficacies in the control and treatment groups were 69.81% and 88.68%, respectively, and there were differences between two groups (P<0.05). After treatment, PT, APTT, and TT levels in two groups were significantly increased, FIB, hs-CRP, and D-dimer levels were decreased, and the difference was statistically significant in the same group (P<0.05). After treatment, the improvement degree of these observational indexes in the treatment group was significantly better than those in the control group, with significant difference between two groups (P<0.05). The recurrence rate within 6 months in the treatment group was obviously lower than those in the control group, and there were differences between two groups (P<0.05). Conclusion Maixuekang Capsules combined with Salviae Miltiorrhizae and Ligustrazine Hydrochloride Injection has a significant clinical efficacy in treatment of transient ischemic attack with less adverse reactions, which has a certain clinical application value.